Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;54(1):666-673.
doi: 10.1080/07853890.2022.2045035.

Neurotrophic keratopathy: current challenges and future prospects

Affiliations
Review

Neurotrophic keratopathy: current challenges and future prospects

Erin NaPier et al. Ann Med. 2022 Dec.

Abstract

Neurotrophic keratopathy (NK), or neurotrophic keratitis, is a degenerative condition that results from decreased innervation to the cornea. The cornea is innervated by the ophthalmic branch of the trigeminal nerve. Neurotrophic keratopathy is most commonly caused by herpes keratitis however, any condition that disrupts the normal corneal innervation can cause NK. Neurotrophic keratopathy is a clinical diagnosis and is classified into three stages based on the disease severity. Stage 1 has mild epithelial defects, such as punctate keratopathy, stage 2 disease has persistent epithelial defects, and stage 3 is defined by the presence of ulcers. Current treatment modalities consist of medical and surgical options. Stage 1 is treated with lubrication through artificial tears, eyelid taping, and punctal plug/cautery. Stage 2 treatment can involve therapeutic contact lenses, topical autologous or allogenic serum, tarsorrhaphy, botulinum toxin injections, and possibly anti-inflammatory medications. Stage 3 disease may require human nerve growth factor, amniotic membrane transplantation, conjunctival flap, or corneal neurotization. New therapies, such as matrix regenerating therapy, plasma rich in growth factors, Thymosin β4, Substance P/Insulin like growth factor-1, and nicergoline represent exciting future options.KEY MESSAGESNeurotrophic keratopathy is a rare degenerative disease defined by decreased innervation to the cornea that is associated with significant morbidity.Treatment options range from lubrication alone to various medical and surgical treatments.Matrix regenerating therapy, plasma rich in growth factors, Thymosin β4, Substance P/Insulin like growth factor-1, and nicergoline are exciting novel therapies that will influence how neurotrophic keratopathy is treated in the future.

Keywords: Mackie classification; Neurotrophic keratitis; autologous serum drops; corneal anaesthesia; corneal nerves; corneal ulcer; neurotization; neurotrophic keratopathy; novel therapies.

PubMed Disclaimer

Conflict of interest statement

No conflicting relationship exists for any author.

Figures

Figure 1.
Figure 1.
Overview of clinical management of neurotrophic keratitis according to the stage of the condition.

References

    1. Bonini S, Rama P, Olzi D, et al. . Neurotrophic keratitis. Eye. 2003;17(8):989–995. - PubMed
    1. Sacchetti M, Lambiase A.. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571–579. - PMC - PubMed
    1. DelMonte DW, Kim T.. Anatomy and physiology of the cornea. J Cataract Refract Surg. 2011;37(3):588–598. - PubMed
    1. Müller LJ, Marfurt CF, Kruse F, et al. . Corneal nerves: structure, contents and function. Exp Eye Res. 2003;76(5):521–542. - PubMed
    1. Sigelman S, Friedenwald JS.. Mitotic and wound-healing activities of the corneal epithelium; effect of sensory denervation. AMA Arch Ophthalmol. 1954;52(1):46–57. - PubMed

LinkOut - more resources